Galactoside Inhibitors for Galectin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current galectin inhibitors face challenges due to their hydrophilicity, susceptibility to acidic hydrolysis, and poor absorption from the gastrointestinal tract, limiting their effectiveness as pharmaceutical compounds for treating inflammation, fibrosis, and cancer.
Innovation Solution
Development of 1,1'-sulfanediyl-di-β-D-galactopyranoside compounds with high affinity for galectin-3 and galectin-1, featuring heterocycles with high pKa values for improved solubility and stability, allowing for effective oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural saccharides are used as galectin inhibitors, then they can bind to galectins, but they are susceptible to acidic hydrolysis and enzymatic degradation
Solution Approach 1:
The patent modifies the chemical structure of natural saccharides by replacing the glycosidic oxygen with a carbon atom (C-C bond) to create C-glycosides. This fundamental chemical parameter change transforms the hydrolytically labile O-glycosidic bond into a stable C-C bond, eliminating susceptibility to acidic hydrolysis while preserving the galactose moiety's ability to bind to galectin carbohydrate recognition domains.
Solution Approach 2:
The patent creates composite molecular structures by combining the stable C-glycoside core with various aromatic substituents (such as pyridyl, phenyl, or heterocyclic groups) at the C-3 position of galactose. These composite structures integrate the binding functionality of natural saccharides with the metabolic stability and enhanced affinity of synthetic aromatic compounds, achieving both high reliability and resistance to degradation.
2Reliability
If hydrophilic saccharides are used as galectin inhibitors, then they can inhibit galectin activity, but they are not readily absorbed from the gastrointestinal tract
Solution Approach 1:
The patent changes the hydrophilicity parameter of saccharide inhibitors by introducing hydrophobic aromatic substituents (such as fluorinated phenyl groups, pyridyl rings, or heterocyclic moieties) at the C-3 position of the galactose unit. This parameter modification reduces overall molecular polarity and enhances lipid solubility, enabling the compounds to cross the gastrointestinal epithelium via passive diffusion while retaining the hydrophilic galactose portion necessary for galectin binding.
3Reliability
If simple galactose derivatives are used, then they can bind to galectins, but they lack sufficient metabolic stability and drug-like properties
Solution Approach 1:
The patent synthesizes composite molecules consisting of a galactose unit (for galectin recognition) linked via a C-C bond to an aromatic substituent (such as 3-substituted phenyl, pyridyl, or heterocyclic groups). This composite structure combines the biological recognition capability of simple galactose derivatives with the metabolic stability, membrane permeability, and pharmacokinetic properties of aromatic drug-like molecules, achieving both high affinity binding and sufficient metabolic stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate high affinity for galectin-3 and galectin-1, offering potent therapeutic potential with enhanced solubility and stability, making them suitable for pharmaceutical formulations to treat various disorders including inflammation, fibrosis, and cancer.
Implementation Method 1
Galectins are proteins with a characteristic carbohydrate recognition domain (CRD)... with the two defining features 1) a β -galactose binding site
Data Source
AI summary
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.